347740.KQ P&K Skin Research Center Co. Ltd

Healthcare Commercial Services & Supplies KOSDAQ
1,811 KRW
Close of Oct 31, 2026
1,292 2,714
Market cap
KRW 52.3B
P/E
14.0x
P/B
0.63x
ROE
7.3%
Dividend yield
1.87%
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 347740.KQ undervalued?

Graham number
Price1,811
Graham value2,877
Discount37.1%

347740.KQ trades 37.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

P&K Skin Research Center Co. Ltd fundamental analysis

9 of 22 checks passed

ROE 0/2

Low return on equity (7.3%), below 10%.

ROA 1/1

Return on assets (6.8%) is above the industry median (2.9%).

Profit Consistency 2/2

Profitable for 8 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-19.4%) is not above the 5-year average (-6.5% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-19.4%) is below the industry median (-5.9%).

Revenue Growth 1/2

Revenue grew 8.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE (14.0x) is above the market median (11.3x).

PE vs Industry 0/1

PE (14.0x) is above the industry median (12.8x).

PBV 0/1

Price to book (0.6x) is above the industry median (0.6x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 8.9, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (1.9%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 20.9%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

P&K Skin Research Center Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About P&K Skin Research Center Co. Ltd

P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vitro tests. It also manufactures and sells raw pharmaceutical and cosmetic materi…

Full company profile